锕-225市场报告：趋势、预测和竞争分析（至2031年）

全球锕-225市场前景光明，得益于科学研究和癌症治疗市场的机会。预计2025年至2031年，全球锕-225市场的复合年增长率将达20.6%。该市场的主要驱动力包括：靶向癌症治疗需求的不断增长、核医学研究的蓬勃发展以及对放射性药物投资的不断增加。

• 根据Lucintel的预测，由于医疗用途的锕-225生产效率高，加速器预计在预测期内将出现强劲成长。
• 从应用角度来看，由于锕-225 在标靶治疗中的应用越来越多，癌症治疗预计将出现高速成长。
• 根据地区划分，由于拥有先进的医疗保健基础设施，预计北美将在预测期内实现最高成长。

锕-225市场的新趋势

由于癌症治疗的新趋势、法规的不断变化以及放射性药物的技术进步，锕-225市场正在快速变化。这些趋势正在改变锕-225在医学上的应用，并创造新的市场。相关人员需要密切关注这些趋势，以便更好地理解它们，为变化做好准备，并抓住它们带来的新机会。

• 癌症标靶治疗资金不断增加：过去几年，锕-225 标靶癌症治疗 (TAT) 的资金投入显着增加。这主要源自于人们日益意识到这些治疗方法能够针对癌细胞，同时最大程度地减少对邻近健康组织的损害。製药公司和医疗机构正在投入大量资金，以确保锕-225 在临床环境中的高效使用。这些投入使锕-225 成为癌症治疗的核心，预计未来几年市场将大幅成长。
• 努力提高产量 随着对锕-225需求的增加，扩大生产规模也成为当务之急。锕-225具有极强的放射性，难以扩大生产规模，尤其是大量生产。但製造流程和技术的改进正在提供帮助。为了满足这一迫切需求，许多公司正在投资建造更先进的生产设施，以应对这种关键材料的日益增长的临床和治疗需求。扩大生产能力对于满足全球对锕-225疗法的需求至关重要。
• 临床试验及其他阶段的改进：令人鼓舞的是，基于锕-225的临床试验正在针对各种癌症进行扩展。初步研究预测了临床试验的需求，预计这些临床试验将以更快的速度通过各种核准流程。各国正逐步努力为其监管机构提供更便捷的核准途径，这可能会缩短锕-225疗法的上市时间，至少对这些国家而言是如此。同样值得注意的是，这种转变将有助于锕-225疗法更快地实现商业性化，以满足肿瘤领域对锕-225疗法日益增长的需求。
• 相关人员之间合作日益密切：锕-225市场正见证着製药公司、研究中心和政府机构之间日益密切的合作。此类伙伴关係对于进行研究、优化生产流程和管理复杂的法规结构至关重要。透过合作，各组织可以充分利用彼此在临床试验和技术推广方面的优势。这些不断扩展的伙伴关係正在形成一个网络，有望加速锕-225疗法在全球的推广。
• 锕-225 与其他治疗方法合併应用：人们越来越关注将锕-225 与化疗和免疫疗法等其他治疗方法合併应用，以改善疗效。锕-225 标靶放射治疗与其他治疗方法合併应用，或能带来更佳的整体癌症治疗方案。这在复杂且侵袭性强的癌症治疗中变得越来越重要，因为这些癌症通常需要多重模式联合治疗。随着研究的深入，将锕-225 与不同的疗法合併应用，有望彻底改变所有类型癌症的治疗方案。

随着研究的深入和市场需求的增加，锕-225 将成为癌症治疗的关键成分。

锕-225市场近期趋势

过去几年，锕-225市场经历了数次变革，显示其在癌症治疗中的价值持续成长。放射性药物研发的进步、研究经费的增加以及相关人员之间的合作是这些变革的主要原因。这些发展改变了锕-225的生产、分销和临床应用方式，旨在改善癌症治疗效果。

• 启动锕-225治疗方法临床试验：锕-225治疗方法的最新进展促使多家製药公司进行多项临床试验，尤其针对摄护腺癌的治疗。这些临床试验结果令人鼓舞，显示有可能以最小的副作用获得理想的临床疗效。如果这些临床试验取得成功，有望加快监管部门的核准，并扩大锕-225疗法在肿瘤学中的应用范围。
• 锕-225生产流程改进：锕-225生产技术取得了重大进展，使大规模生产更加切实可行。标靶和精製製程的改进提高了锕-225的产量和纯度。这些改进解决了早期存在的生产问题，对于满足全球日益增长的锕-225疗法需求至关重要。
• 与研究机构建立策略联盟：製药公司越来越多地与研究机构建立策略联盟，以快速开发和商业化锕-225疗法。这些合作旨在加强临床试验阶段、改善生产流程并进行临床前试验。这种合作正在加速开发有效的锕-225治疗方法并将其及时推向市场的进程。
• 启动标靶治疗监管政策：监管机构正在考虑市场对标靶治疗（尤其是基于锕-225的标靶治疗）日益增长的兴趣，并正在扩大其应用范围。简化锕-225治疗方法的核准流程，是缩短病患获得治疗方法时间的重要一步。这在美国和欧洲等地区至关重要，因为这些地区的监管核准与市场渗透率和接受度密切相关。
• 锕-225研究经费增加：新的进展凸显了锕-225作为癌症标靶治疗的潜在潜力，推动了研究经费的增加。政府机构、私人公司投资者，甚至製药公司都在加大投入，探索锕-225在肿瘤学中的新用途。因此，更多的投资正在推动治疗方法的创新，并最终推动生产和临床应用技术的创新，从而加速基于锕-225的治疗方法的开发。

这些进展提升了人们对锕-225在医学领域，尤其是在癌症治疗领域应用的兴趣。临床试验、生产流程的改进、战略伙伴关係的建立以及政府的倡导，都旨在实现锕-225的潜力，并使其在癌症标靶治疗不断拓展的应用范围。

目录

第一章执行摘要

第二章 全球锕-225市场：市场动态

• 简介、背景和分类
• 供应链
• 产业驱动力与挑战

第三章市场趋势与预测分析（2019-2031）

• 宏观经济趋势（2019-2024）及预测（2025-2031）
• 全球锕-225市场趋势（2019-2024年）及预测（2025-2031年）
• 全球锕-225市场（按类型）
  • 加速器
  • 钍-229崩坏
• 全球锕-225市场（按应用）
  • 科学研究
  • 癌症治疗

第四章区域市场趋势与预测分析（2019-2031）

• 全球锕-225市场（按区域）
• 北美锕-225市场
• 欧洲锕-225市场
• 亚太锕-225市场
• 世界其他地区的锕-225市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析
• 市场占有率分析

第六章 成长机会与策略分析

• 成长机会分析
  • 全球锕-225市场成长机会（按类型）
  • 全球锕-225市场成长机会（按应用）
  • 全球锕-225市场成长机会（按地区）
• 全球锕-225市场的新趋势
• 战略分析
  • 新产品开发
  • 全球锕-225市场产能扩张
  • 全球锕-225 市场的企业合併
  • 认证和许可

第七章主要企业简介

• ORNL
• Tri-Lab
• SSC RF-IPPE
• JRC Karlsruhe
• TerraPower
• TRIUMF
• Eckert&Ziegler

The future of the global actinium-225 market looks promising with opportunities in the scientific research and cancer therapy markets. The global actinium-225 market is expected to grow with a CAGR of 20.6% from 2025 to 2031. The major drivers for this market are the increasing demand for targeted cancer therapies, the rising research in nuclear medicine, and the growing investments in radiopharmaceuticals.

• Lucintel forecasts that, within the type category, accelerator is expected to witness higher growth over the forecast period due to their efficiency in producing actinium-225 for medical applications.
• Within the application category, cancer therapy is expected to witness higher growth due to the increasing use of actinium-225 in targeted treatments.
• In terms of region, North America is expected to witness the highest growth over the forecast period due to the presence of advanced healthcare infrastructure in thi region.

Emerging Trends in the Actinium-225 Market

The actinium-225 market is transforming at a fast pace with newer trends pertaining to cancer treatment, changes in the law, and technological improvements in radiopharmaceuticals. These trends are changing the application of actinium-225 in medicine as well as creating new markets. To understand and prepare for the changes as well as take advantage of the new opportunities these trends are creating, stakeholders need to closely monitor them.

• Growing Funding for Targeted Cancer Treatment: Investment funding in targeted cancer treatment (TAT) with actinium-225 has significantly increased over the past years. This is primarily due to the growing awareness of the potential of these therapies to target cancerous cells while causing minimal damage to the adjacent healthy tissues. Pharmaceutical companies and medical institutions are investing a lot of money into ensuring that the use of actinium-225 in clinical settings is as efficient as possible. With these investments, the market is predicted to grow significantly in the coming years, with actinium-225 being a central part of cancer therapies.
• Make an Effort to Increase Production: At the same time there is demand increase for Actinium-225, there is a growing emphasis on scaling production. The extreme radioactivity of actinium-225 makes it particularly difficult to scale production, particularly but improvements in manufacturing processes and technology are helping. In order to keep up with this urgent need, many companies are investing into more sophisticated production facilities for this critical material so that supply can be matched with the growing clinical and therapeutic needs. The scale at which production capabilities are expanded is integral in meeting the global demand for actinium-225 therapies.
• Improvement in Clinical Trials and Other Stages: There is an expanding array of actinium-225 based therapy clinical trials for various forms of cancer, which is an encouraging sign. Given the projected demand for clinical trials in the preliminary studies, we expect that they will move forward at a faster pace through various approval processes. Different countries are progressively trying to provide better approval pathways for the regulators which is likely, at least for the country, to lower the time needed for actinium-225 therapies to be marketed. It is also important to note that in meeting the increasing demand for actinium-225 therapies in oncology, this shift will help make them commercially available more quickly.
• Increasing Cooperation among Stakeholders: The cooperation of pharmaceutical firms, research centers, and government agencies is increasing in the actinium-225 market. These partnerships are important for the development of research, the optimization of production processes, and the management of the complex regulatory framework. Organizations can capitalize on each other's strengths in clinical trials and technology distribution through collaboration. These growing partnerships are forming a network which has the potential to facilitate adoption of actinium-225 therapies around the world.
• Use of Actinium-225 with other Therapeutic Modalities: The interest in pairing actinium-225 with other therapeutic modalities such as chemotherapy or immunotherapy, in order to improve treatment results, is growing. Targeted radiation of actinium-225 infused with other treatment modalities has the potential of producing better and holistic cancer treatment options. This is becoming increasingly important in the management of complex and high-grade cancers that often require a multi-modality approach. With continuous research, combining different methods with actinium-225 is bound to change the treatment of cancers of all forms.

These changes are shifting the current landscape of the actinum-225 market through the broadening of production and therapeutic use, as well as collaboration between important parties. actinium-225 is being positioned as an important component in the treatment of cancer as research continues and market demand grows.

Recent Developments in the Actinium-225 Market

Over the past few years, the actinium-225 market has undergone a few changes that demonstrate its continually increasing value in cancer treatment. Progresses in research and development of radiopharmaceuticals, heightened spending on research, and collaboration amongst industry stakeholders are the primary reasons for these changes. These developments are changing the method of production, distribution, and clinical application of actinium-225 with the intention of improving cancer treatment results.

• Initiation of clinical trials for actinium-225 based therapies: Actinium-225 based therapies have recently witnessed the development of multiple clinical trials staged by several pharmaceutical companies aimed at managing prostate cancer, amongst others. These trials demonstrate encouraging results and suggest the possibility of achieving desired clinical outcomes with minimal side effects. If successful, these clinical trials will likely result in expedited regulatory approval and broader application of actinium-225 treatments in oncology.
• Improvements in the technology of actinium-225 production: The technology employed in the production of actinium-225 has upgraded considerably, which makes large scale production more practical. Improvements in target and purification processes are increasing the yield and purity of actinium-225, which is vital for its use in medical applications. These improvements are addressing production issues that existed in the earlier phases and are important to fulfill the growing demand for actinium-225-based therapies around the world.
• Strategic collaborations with research agencies: Pharmaceutical firms are forming more and more strategic collaborations with research agencies for faster development and commercialization of actinium-225 therapies. These collaborations are aimed at enhancing the clinical trials' stage, improving the production processes, and performing preclinical studies. This collaboration is speeding up the process of developing effective actinium-225 therapies and bringing them to the market in a timely manner.
• Launch of regulatory policies for targeted treatments: Regulatory authorities are widening their scope of coverage to take into account the increasing interest in targeted treatments, particularly those with the use of actinium-225. The simplification of the procedures for approval of actinium-225 based treatments is one step towards shortening the time it takes to get therapies to patients. This is crucial in parts of the world like the United States of America and Europe where regulatory approvals have a huge bearing on market penetration and acceptance.
• Enhanced Capital for actinium-225 Research: New developments show that actinium-225 is getting increased attention as a possible targeted cancer treatment, which is why funding for research is increasing. Government agencies, private sector investors, and even pharmaceutical companies are pouring more money towards finding new uses of actinium-225 in Oncology. As a result, more investment is helping to foster greater innovation in treatment methods and consequently, technologies for production and clinical applications as well, which leads to accelerated development of therapies based on actinium-225.

All of these developments justify the increased attention towards actinium-225 in medicine, and particularly, in the treatment of cancer. The improving clinical trials, production processes, strategic partnerships, and governmental advocacy all aim towards fulfilling the promise of actinium-225 and his ever-expanding domains in targeted therapies for cancers.

Strategic Growth Opportunities in the Actinium-225 Market

The variety of applications, especially in oncology and radiopharmaceuticals, makes the actinium-225 market a candidate for strategic growth opportunities. The growing trends whereby more sophisticated targeted therapies for cancer are developed makes actinium-225 a very important weapon in the fight against cancer. The expansion of production, new clinical applications, and the increase in innovation by stakeholders all enable these opportunities to be utilized.

• Cancer Treatment Uses: The need for well-targeted therapies to treat cancer gives a considerable market opportunity for actinium-225. It is a promising candidate for cancer treatment because of its ability to irradiate tissues that contain tumor cells with little collateral damage to the surrounding healthy tissues. Focused research on the application of actinium-225 in prostate, ovarian, and lung cancer will greatly enhance the market and revenue potential for pharmaceutical companies.
• Cooperation with Biotech Companies: There exists also other important actinium-225 market expansion opportunities with pharmaceutical companies collaborating with biotech firms. Larger pharmaceutical companies stand to capture the biopharmaceuticals market by working with companies that deal with radiopharmaceuticals. These collaborations improve the business transactions of sharing knowledge and resources greatly enhancing the processes of clinical trials and expand the market for actinium-225 based therapies.
• Bolstering production capacity: To address the increasing demand for actinium-225, there is an investment in the expansion of production infrastructure. In so doing, there will be an enhancement of production facilities as well as more sophisticated manufacturing technologies. By increasing the supply of this commodity, the market is able to guarantee the continuous supply of actinium-225 for clinical use which will facilitate the wider use of this advanced treatment in hospitals and cancer centers all over the globe.
• Market entry and regulation: Actinium-225 radiopharmaceuticals represent one of the most important strategic business development opportunities which come from the business of obtaining regulatory approvals that would accelerate the entry of the market for actinium-225 therapies. By collaborating with regulatory agencies, companies would be able to enable faster marketing of their products by simplifying the approval processes. This would grant easier access to using Actinium-225-based therapies and create chances for international growth while cementing the position of companies as frontrunners in targeted therapy.
• Global market growth: There is a marked potential improvement in healthcare systems as well as an increasing demand for cancer treatment in some regions in Asia and Latin America which provides untapped markets for actinium-225 therapies. These regions stand to benefit greatly from using actinium-225 in their cancer treatments. To maximize long term growth prospects, these companies need to rapidly invest in establishing local partnerships and distribution networks to build brand presence globally.

The production growths and new applications for treatment of other cancers are two aspects that showcase the vast opportunities in the market of actinium-225. Stakeholders will be able to utilize these opportunities for innovative growth of market share and effective strategic results toward the development of cancer therapies.

Actinium-225 Market Driver and Challenges

As with any market, the actinium-225 market has a number of factors - technical, economic or regulatory in nature - that influence its growth positively or negatively. As issue can be used as an opportunity if properly understood, analyzed and followed up with corresponding research activity. There is no question that such activity would determine the environment within which the actinium-225 market will grow or shrink in the future.

The factors responsible for driving the actinium-225 market include:

1. Radiopharmaceuticals production and other technology improvements: One of the primary drivers of the actinium-225 market is the straightforward improvement in production and delivery methods of radiopharmaceuticals. Newer techniques of the production technology make it economically viable to produce actinium-225 in bulk while newer systems for radiation delivery are more proficient in targeting particular cancer cells. The advancement allows for actinium-225 to be more readily available and effective to be used in medical treatments.

2. Enhanced focus on effective therapies: Targeted therapies in utilizing actinium-225 are on the rise as demand for precise cancer treatment continues to intensify. These therapies enable the delivery of radiation treatment to the tumor site only, which lessens the damage caused to the adjacent healthy tissues. The global health care shift towards personalized medicine is creating demand for actinium-225 based therapies and making them a prominent solution to targeted cancer treatment.

3. Global market for cancer treatment services is evolving: Growing cases of cancer disease across the world is contributing to the evolving cancer treatment market, which provides ample opportunities for Actinium-225. More and more patients are looking for novel therapeutic interventions, creating opportunities for exploring actinium-225 to tackle different types of cancer, including the more advanced stages that are more difficult to treat. Enhanced focus on research and treatment of cancer has a positive correlation with the emerging market of Actinium-225.

4. Increase in funding directed towards R&D activities: Increased funding directed towards research and development in the field of oncology and radiopharmaceuticals is positively impacting growth of Actinium-225. The more funds that pharmaceutical companies and research institutions spend on studying this element, the more developed and novel therapies will be available. Clinical investigations, regulatory approvals, and new usages of actinium-225 are being propelled by these funds.

5. Encouraging regulatory frameworks: Regulatory agencies remain more favorable towards the introduction for the development and for the approval of new cancer therapies, including those using Actinium-225. The commercialized therapies based on actinium-225 are being accelerated due to streamlined approval processes and fast track pathways for breakthrough therapies. Such favorable environments has also encouraged investment in research projects, production, and clinical trials which are fueling market growth.

Challenges in the actinium-225 market are:

1. Cost of production is high: The production of actinium-225 is still expensive due to the complexity associated with its synthesis and the specialized equipment that is needed. High production costs present a barrier to making actinium-225 based therapies widely available and affordable, particularly in emerging economies. These cost challenges need to be overcome if greater adoption and scale of actinium-225 therapies is to be achieved.

2. Limited availability and supply chain issues: The supply of actinium-225 is currently limited due to challenges in production capacity and supply chain logistics. As demand continues to grow, it will be vital to ensure a dependable and consistent supply of Actinium-225. These supply chain bottlenecks and increase production capacity will need to be dealt with in order to satisfy the market's demands and avoid shortages in the future.

3. Roadblocks in Regulations on Emerging Markets: Actinium-225's potential use in therapy could be restricted in areas with less developed medical care and regulatory systems because of inadequate adoption surrounding treatments of Actinium-225. Obtaining the required licenses for actinium-225 therapies and navigating through the regulatory frameworks can be quite tedious and expensive. Emerging markets are often characterized by slower and more complicated approval processes for new treatment technologies, which poses a barrier that is extremely difficult to overcome.

Both the competitive landscape of targeted therapies and cancer care therapeutics fuel the demand for actinium-225. At the same time, technological advances are opening new opportunities in the market. In order to achieve sustained success and growth, Actinium-225 must ready itself in meeting the difficulties posed by abundance of regulations, scarcity of resources, and high production costs, especially in the medical treatment field.

List of Actinium-225 Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies actinium-225 companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the actinium-225 companies profiled in this report include-

• ORNL
• Tri-Lab
• SSC RF-IPPE
• JRC Karlsruhe
• TerraPower
• TRIUMF
• Eckert&Ziegler

Actinium-225 Market by Segment

The study includes a forecast for the global actinium-225 market by type, application, and region.

Actinium-225 Market by Type [Value from 2019 to 2031]:

• Accelerator
• Thorium-229 Decay

Actinium-225 Market by Application [Value from 2019 to 2031]:

• Scientific Research
• Cancer Therapy

Actinium-225 Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Actinium-225 Market

The market for actinium-225 is changing rapidly in important countries due to its application in targeted alpha therapy (TAT) for cancer treatment. With improvement in medical research and technology, actinium-225 is being used more and more for localized radiation therapy. With the increased use of radiation therapy, interest from healthcare providers, pharmaceutical companies, and regulatory bodies is on the rise. Countries such as the United States, China, Germany, India, and Japan are simultaneously experiencing changes which are influencing the rest of the market and furthering the efforts in clinical trials, production, and regulation of this market.

• United States: In the United States, actinium-225 is receiving a lot of attention as a possible option for targeted cancer therapies. There has been considerable investment in research and development in the U.S., especially in the clinical trials for the use of actinium-225 for treating cancers such as prostate cancer. In addition to this, pharmaceutical partnerships and research collaborations are aiding the supply of actinium-225. In the United States, the regulators' interest has also shifted towards the streamlining of approvals of therapies which has resulted in the FDA/CMS collaborative agreement. Due to all these increased activities, it can be said that the United States is expected to dominate the advancement of clinical applications for actinium-225.
• China: Due to the growth of the healthcare and biotechnological fields, China's role in the actinium-225 market has heightened. The country is seeing faster paced research into actinium-225 as part of its wider efforts to advance cancer treatment technologies. Chinese pharmaceutical companies are seeking collaboration with foreign partners to establish actinium-225-based therapies, and interest in clinical trials is also growing. Nonetheless, regulatory burdens and insufficiently developed production and logistics infrastructures remain the major issues that hinder wider implementation within the healthcare system.
• Germany: German's remarkable achievement in medical research and pharmaceuticals has increased the country's involvement in the European actinium-225 market. The country has many research entities that study nuclear medicine and oncology, where actinium-225 is being investigated for its use in targeted cancer therapy. Furthermore, Germany's regulations are becoming more favorable for the novel therapies increasing the ease for clinical trials with actinium-225 to be conducted. Along with these developments, the country is also noted for having a sound healthcare system that constantly seeks to utilize modern medical technologies, which strengthens Germany's position in the region.
• India: For India's expanding medical and pharmaceutical industries, actinium-225 poses a lucrative opportunity. Radiopharmaceuticals are being widely adopted, and there is an increase in merger activities with foreign institutions for research and clinical trials. As the country aims to improve its cancer treatments, it plans to research the use of actinium-225 in theragnostic for treating different types of tumors. Indian industries are facing delays in the achievement of infrastructural components and regulatory approvals, unlike other countries, which hinders the wide adoption of actinium-225 on a global scale in the medical field.
• Japan: His country is making rapid strides in the field of nuclear medicine, and the use of actinium-225 is no exception. Japan is working on developing alpha targeted therapies for cancer, and actinium-225 is one of the principal components. The country with its predominating and advanced pharmaceutical and healthcare sector is one of the leaders in innovation and new treatment paradigms. The use of actinium-225 for therapeutic uses is being integrated within the treatment framework faster due to the supportive medical technology policy and established clinical research infrastructure, but there exist problems of manufacture and scalability in the supply chain.

Features of the Global Actinium-225 Market

Market Size Estimates: Actinium-225 market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Actinium-225 market size by type, application, and region in terms of value ($B).

Regional Analysis: Actinium-225 market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the actinium-225 market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the actinium-225 market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the actinium-225 market by type (accelerator and thorium-229 decay), application (scientific research and cancer therapy), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Actinium-225 Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Actinium-225 Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Actinium-225 Market by Type
  • 3.3.1: Accelerator
  • 3.3.2: Thorium-229 Decay
• 3.4: Global Actinium-225 Market by Application
  • 3.4.1: Scientific Research
  • 3.4.2: Cancer Therapy

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Actinium-225 Market by Region
• 4.2: North American Actinium-225 Market
  • 4.2.1: North American Market by Type: Accelerator and Thorium-229 Decay
  • 4.2.2: North American Market by Application: Scientific Research and Cancer Therapy
  • 4.2.3: The United States Actinium-225 Market
  • 4.2.4: Canadian Actinium-225 Market
  • 4.2.5: Mexican Actinium-225 Market
• 4.3: European Actinium-225 Market
  • 4.3.1: European Market by Type: Accelerator and Thorium-229 Decay
  • 4.3.2: European Market by Application: Scientific Research and Cancer Therapy
  • 4.3.3: German Actinium-225 Market
  • 4.3.4: French Actinium-225 Market
  • 4.3.5: The United Kingdom Actinium-225 Market
• 4.4: APAC Actinium-225 Market
  • 4.4.1: APAC Market by Type: Accelerator and Thorium-229 Decay
  • 4.4.2: APAC Market by Application: Scientific Research and Cancer Therapy
  • 4.4.3: Chinese Actinium-225 Market
  • 4.4.4: Japanese Actinium-225 Market
  • 4.4.5: Indian Actinium-225 Market
  • 4.4.6: South Korean Actinium-225 Market
  • 4.4.7: Taiwan Actinium-225 Market
• 4.5: ROW Actinium-225 Market
  • 4.5.1: ROW Market by Type: Accelerator and Thorium-229 Decay
  • 4.5.2: ROW Market by Application: Scientific Research and Cancer Therapy
  • 4.5.3: Brazilian Actinium-225 Market
  • 4.5.4: Argentine Actinium-225 Market

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis
• 5.4: Market Share Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Actinium-225 Market by Type
  • 6.1.2: Growth Opportunities for the Global Actinium-225 Market by Application
  • 6.1.3: Growth Opportunities for the Global Actinium-225 Market by Region
• 6.2: Emerging Trends in the Global Actinium-225 Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Actinium-225 Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Actinium-225 Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: ORNL
• 7.2: Tri-Lab
• 7.3: SSC RF-IPPE
• 7.4: JRC Karlsruhe
• 7.5: TerraPower
• 7.6: TRIUMF
• 7.7: Eckert&Ziegler